Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Carisma Therapeutics Inc CARM.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -46 cents. The lone analyst forecast for the quarter was for a loss of 12 cents per share.

• Revenue rose 9.8% to $3.73 million from a year ago; analysts expected $3.75 million.

• Carisma Therapeutics Inc's reported EPS for the quarter was a loss of 22 cents​.

• Carisma Therapeutics Inc shares had fallen by 40.1% this quarter and lost 55.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 33.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "hold."

• Wall Street's median 12-month price target for Carisma Therapeutics Inc is $1.00

This summary was machine generated from LSEG data May 14 at 09:23 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)